

# SENTARA COMMUNITY PLAN (MEDICAID)

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

### Non-Preferred Adalimumab Products (Pharmacy)

**Drug Requested:** (Select drug requested below)

<input type="checkbox"/> <b>Abrilada</b> <sup>®</sup> (adalimumab-afzb)	<input type="checkbox"/> <b>Amjevita</b> <sup>®</sup> (adalimumab-atto)	<input type="checkbox"/> <b>Cyltezo</b> <sup>®</sup> (adalimumab-adbm)
<input type="checkbox"/> <b>Hadlima</b> <sup>®</sup> (adalimumab-bwwd)	<input type="checkbox"/> <b>Hulio</b> <sup>®</sup> (adalimumab-fkjp)	<input type="checkbox"/> <b>adalimumab-fkjp</b> (generic for Hulio <sup>®</sup> )
<input type="checkbox"/> <b>Hyrimoz</b> <sup>®</sup> (adalimumab-adaz)	<input type="checkbox"/> <b>adalimumab-adaz</b> (generic for Hyrimoz <sup>®</sup> )	<input type="checkbox"/> <b>Idacio</b> <sup>®</sup> (adalimumab-aacf)
<input type="checkbox"/> <b>adalimumab-aacf</b> (generic for Idacio <sup>®</sup> )	<input type="checkbox"/> <b>Simlandi</b> <sup>®</sup> (adalimumab-ryvk	<input type="checkbox"/> <b>Yuflyma</b> <sup>®</sup> (adalimumab-aaty)
<input type="checkbox"/> <b>Yusimry</b> <sup>®</sup> (adalimumab-aqvh)	)	

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member Sentara #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Name/Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight (if applicable): \_\_\_\_\_ Date weight obtained: \_\_\_\_\_

**NOTE:** The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

(Continued on next page)

Diagnosis	Recommended Dose/ Quantity Limit
<b>Rheumatoid Arthritis/Juvenile Idiopathic Arthritis/Psoriatic Arthritis/Ankylosing Spondylitis</b>	<ul style="list-style-type: none"> <li>• Quantity Limit:               <ul style="list-style-type: none"> <li>○ Two, syringes/pen per 28 days.</li> </ul> </li> </ul>
<b>Adult Crohn's Disease/Ulcerative Colitis</b>	<ul style="list-style-type: none"> <li>• Quantity Limit:               <ul style="list-style-type: none"> <li>○ Six, syringes/pen in the initial 28 days.</li> <li>○ Two, syringes/pen per 28 days after induction period.</li> </ul> </li> </ul>
<b>Pediatric Crohn's Disease</b>	<ul style="list-style-type: none"> <li>• <b>37lbs to &lt; 88lbs:</b> <ul style="list-style-type: none"> <li>• Quantity limit Initial month:                   <ul style="list-style-type: none"> <li>○ One, syringe/pen 20mg, 40mg or 80mg.</li> </ul> </li> <li>• Maintenance                   <ul style="list-style-type: none"> <li>○ Two, syringes/pen 20mg per 28 days.</li> </ul> </li> </ul> </li> <li>• <b>≥ 88lbs:</b> <ul style="list-style-type: none"> <li>• Quantity limit Initial month:                   <ul style="list-style-type: none"> <li>○ One, syringe/pen 40mg, 80mg or 160mg.</li> </ul> </li> <li>• Maintenance:                   <ul style="list-style-type: none"> <li>○ Begin a maintenance dose of Two, syringes/pen 40mg every 28 days.</li> </ul> </li> </ul> </li> </ul>
<b>Plaque Psoriasis</b>	<ul style="list-style-type: none"> <li>• Quantity Limit:               <ul style="list-style-type: none"> <li>○ Four, syringes/pen in the initial 28 days.</li> <li>○ Two, syringes/pen per 28 days after induction period.</li> </ul> </li> </ul>
<b>Hidradenitis Suppurativa Adults</b>	<ul style="list-style-type: none"> <li>• 160 mg day 1, followed by 80 mg day 15 (6 syringes/28 days) for induction period, thereafter 40 mg once a week starting day 29 (4 syringes/28 days)</li> </ul>
<b>Hidradenitis Suppurativa Children 12-17 years old</b>	<ul style="list-style-type: none"> <li>• <b>30kg to 59kg:</b> <ul style="list-style-type: none"> <li>• Quantity limit Initial:                   <ul style="list-style-type: none"> <li>○ 80mg on day one.</li> </ul> </li> <li>• Maintenance                   <ul style="list-style-type: none"> <li>○ 40 mg once every other week starting on day 29.</li> </ul> </li> </ul> </li> <li>• <b>≥ 60kg:</b> <ul style="list-style-type: none"> <li>• Quantity limit Initial:                   <ul style="list-style-type: none"> <li>○ 160 mg day 1, followed by 80 mg day 15(6 syringes/28 days) for induction period.</li> </ul> </li> <li>• Maintenance:                   <ul style="list-style-type: none"> <li>○ 40 mg once a week starting on day 29 (4 syringes/28 days).</li> </ul> </li> </ul> </li> </ul>

(Continued on next page)

Diagnosis	Recommended Dose/ Quantity Limit
Uveitis	<p><b>Adults:</b></p> <ul style="list-style-type: none"> <li>• Quantity limit Initial:                             <ul style="list-style-type: none"> <li>◦ Four syringes in the initial 28 days.</li> </ul> </li> <li>• Maintenance                             <ul style="list-style-type: none"> <li>◦ Two syringes/ pens per 28 days after induction period.</li> </ul> </li> </ul> <p><b>Children 2-17 years old:</b></p> <ul style="list-style-type: none"> <li>• <b>10kg-14kg:</b> <ul style="list-style-type: none"> <li>• Quantity limit:                                     <ul style="list-style-type: none"> <li>◦ 10 mg every other week</li> </ul> </li> </ul> </li> <li>• <b>15kg-29kg:</b> <ul style="list-style-type: none"> <li>• Quantity limit:                                     <ul style="list-style-type: none"> <li>◦ 20 mg every other week</li> </ul> </li> </ul> </li> <li>• <b>30kg:</b> <ul style="list-style-type: none"> <li>• Quantity limit:                                     <ul style="list-style-type: none"> <li>◦ 40 mg every other week</li> </ul> </li> </ul> </li> </ul>

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

**Diagnosis: Moderate-to-Severe Rheumatoid Arthritis**

- Member has a diagnosis of moderate-to-severe **rheumatoid arthritis**
- Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Enbrel®	<input type="checkbox"/> Infliximab
----------------------------------	----------------------------------	-------------------------------------

**Diagnosis: Moderate-to-Severe Active Polyarticular Juvenile Idiopathic Arthritis**

- Member has a diagnosis of moderate-to-severe active polyarticular **juvenile idiopathic arthritis**
- Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Enbrel®	<input type="checkbox"/> Infliximab
----------------------------------	----------------------------------	-------------------------------------

(Continued on next page)

**Diagnosis: Active Psoriatic Arthritis**

- Member has a diagnosis of active **psoriatic arthritis**
- Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Enbrel®	<input type="checkbox"/> Infliximab
----------------------------------	----------------------------------	-------------------------------------

**Diagnosis: Active Ankylosing Spondylitis**

- Member has a diagnosis of active **ankylosing spondylitis**
- Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Enbrel®	<input type="checkbox"/> Infliximab
----------------------------------	----------------------------------	-------------------------------------

**Diagnosis: Moderate-to-Severe Active Crohn's Disease (CD)**

- Member has a diagnosis of moderate-to-severe active **Crohn's disease**
- Member has tried and failed both:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Enbrel®
----------------------------------	----------------------------------

**Diagnosis: Moderate-to-Severe Ulcerative Colitis (UC)**

- Member has a diagnosis of moderate-to-severe active **Crohn's disease**
- Member has tried and failed both:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Infliximab
----------------------------------	-------------------------------------

(Continued on next page)

**Diagnosis: Moderate-to-Severe Chronic Plaque Psoriasis**

- Member has a diagnosis of moderate-to-severe chronic **plaque psoriasis**
- Trial and failure of **TWO (2)** of the **PREFERRED** drugs below:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Enbrel®	<input type="checkbox"/> Infliximab
----------------------------------	----------------------------------	-------------------------------------

**Diagnosis: Moderate-to-Severe Hidradenitis Suppurativa (HS)**

- Member has a diagnosis of moderate-to-severe **hidradenitis suppurativa**
- Trial and failure of Humira®

**Diagnosis: Uveitis (UV)**

- Member has a diagnosis of **Uveitis**
- Member has tried and failed both:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Infliximab
----------------------------------	-------------------------------------

**Medication being provided by a Specialty Pharmacy – Proprium Rx**

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****